Actuate Therapeutics Files IPO Amendment

Ticker: ACTU · Form: S-1/A · Filed: Jul 23, 2024 · CIK: 1652935

Actuate Therapeutics, Inc. S-1/A Filing Summary
FieldDetail
CompanyActuate Therapeutics, Inc. (ACTU)
Form TypeS-1/A
Filed DateJul 23, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$8.00, $10.00, $1.0 billion
Sentimentneutral

Sentiment: neutral

Topics: ipo, amendment, pharmaceutical

TL;DR

Actuate Therapeutics (fka Apotheca) filed S-1/A for IPO. Details on shares/pricing TBD.

AI Summary

Actuate Therapeutics, Inc. filed an S-1/A amendment on July 23, 2024, for its initial public offering. The company, formerly known as Apotheca Therapeutics, Inc. until September 11, 2015, is seeking to register an unspecified number of shares. The filing indicates the company's principal executive offices are located at 1751 River Run, Suite 400, Fort Worth, Texas 76107, with a business phone number of (817) 887-8455.

Why It Matters

This S-1/A filing provides updated information for Actuate Therapeutics' potential initial public offering, which could bring new investment into the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a company undergoing an IPO, Actuate Therapeutics faces inherent risks related to market reception, regulatory approvals, and competitive pressures in the pharmaceutical industry.

Key Numbers

  • 333-279734 — SEC File Number (Identifies the specific registration statement)
  • 0001652935 — Central Index Key (Unique identifier for the filer)

Key Players & Entities

  • ACTUATE THERAPEUTICS, INC. (company) — Registrant
  • Apotheca Therapeutics, Inc. (company) — Former company name
  • 20150911 (date) — Date of name change
  • July 23, 2024 (date) — Filing date
  • 1751 River Run, Suite 400 Fort Worth, Texas 76107 (location) — Principal executive offices
  • 817-887-8455 (phone_number) — Business phone number
  • Daniel Schmitt (person) — President and Chief Executive Officer

FAQ

What is the purpose of this S-1/A filing?

This is an Amendment No. 5 to the Form S-1 Registration Statement filed by Actuate Therapeutics, Inc. to update information related to its initial public offering.

When was Actuate Therapeutics, Inc. previously known by another name?

The company was formerly known as Apotheca Therapeutics, Inc. until September 11, 2015.

Where are Actuate Therapeutics' principal executive offices located?

The principal executive offices are located at 1751 River Run, Suite 400, Fort Worth, Texas 76107.

Who is the President and Chief Executive Officer of Actuate Therapeutics?

Daniel Schmitt serves as the President and Chief Executive Officer.

What is the SEC file number for this registration statement?

The SEC file number is 333-279734.

Filing Stats: 4,457 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-07-23 06:01:18

Key Financial Figures

  • $8.00 — r share of common stock will be between $8.00 and $10.00. Prior to this offering, t
  • $10.00 — common stock will be between $8.00 and $10.00. Prior to this offering, there has be
  • $1.0 billion — roducts and executed over approximately $1.0 billion in milestone value through licensing, a

Filing Documents

RISK FACTORS

RISK FACTORS 14 INDUSTRY AND MARKET DATA 72

USE OF PROCEEDS

USE OF PROCEEDS 73 DIVIDEND POLICY 75 CAPITALIZATION 76

DILUTION

DILUTION 79 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 82

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 83

BUSINESS

BUSINESS 100 MANAGEMENT 154

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 164 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 175 PRINCIPAL SECURITYHOLDERS 179

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 183 SHARES ELIGIBLE FOR FUTURE SALE 190 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 193

UNDERWRITING

UNDERWRITING 197 LEGAL MATTERS 206 EXPERTS 206 WHERE YOU CAN FIND MORE INFORMATION 206 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus. Neither we nor the underwriters have authorized anyone to provide you with different information and, if provided, such information or representations must not be relied upon as having been authorized by us or the underwriters. This prospectus shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. You should read this prospectus together with the additional information described below under the heading "Where You Can Find More Information." We may also provide a prospectus supplement or post-effective amendment to the Registration Statement to add information to, or update or change information contained in, this prospectus. The information contained in this prospectus, or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. This prospectus does not contain all of the information included in the Registration Statement. For a more complete understanding of the offering of the securities, you should refer to the Registration Statement, including its exhibits. This prospectus includes our trademarks, and trade names, including but not limited to Actuate and Actuate Therapeutics, which are protected under applicable intellectual property laws. This prospectus also may contain trademarks, service marks, trade names, and copyrights of other companies, which are the property of their respective owners. Solely for convenience, the trademarks, service marks, trade names, and copyrights referred to in this prospectus are li

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.